IBDEI0JE ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8726,1,3,0)
;;=3^Personal Hx of Malig Neop of Bladder
;;^UTILITY(U,$J,358.3,8726,1,4,0)
;;=4^Z85.51
;;^UTILITY(U,$J,358.3,8726,2)
;;=^5063428
;;^UTILITY(U,$J,358.3,8727,0)
;;=Z85.528^^39^402^83
;;^UTILITY(U,$J,358.3,8727,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8727,1,3,0)
;;=3^Personal Hx of Malig Neop of Kidney
;;^UTILITY(U,$J,358.3,8727,1,4,0)
;;=4^Z85.528
;;^UTILITY(U,$J,358.3,8727,2)
;;=^5063430
;;^UTILITY(U,$J,358.3,8728,0)
;;=Z85.6^^39^402^74
;;^UTILITY(U,$J,358.3,8728,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8728,1,3,0)
;;=3^Personal Hx of Leukemia
;;^UTILITY(U,$J,358.3,8728,1,4,0)
;;=4^Z85.6
;;^UTILITY(U,$J,358.3,8728,2)
;;=^5063434
;;^UTILITY(U,$J,358.3,8729,0)
;;=Z85.72^^39^402^98
;;^UTILITY(U,$J,358.3,8729,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8729,1,3,0)
;;=3^Personal Hx of Non-Hodgkin Lymphomas
;;^UTILITY(U,$J,358.3,8729,1,4,0)
;;=4^Z85.72
;;^UTILITY(U,$J,358.3,8729,2)
;;=^5063436
;;^UTILITY(U,$J,358.3,8730,0)
;;=Z85.79^^39^402^88
;;^UTILITY(U,$J,358.3,8730,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8730,1,3,0)
;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
;;^UTILITY(U,$J,358.3,8730,1,4,0)
;;=4^Z85.79
;;^UTILITY(U,$J,358.3,8730,2)
;;=^5063437
;;^UTILITY(U,$J,358.3,8731,0)
;;=Z85.820^^39^402^77
;;^UTILITY(U,$J,358.3,8731,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8731,1,3,0)
;;=3^Personal Hx of Malig Melanoma of Skin
;;^UTILITY(U,$J,358.3,8731,1,4,0)
;;=4^Z85.820
;;^UTILITY(U,$J,358.3,8731,2)
;;=^5063441
;;^UTILITY(U,$J,358.3,8732,0)
;;=Z85.828^^39^402^92
;;^UTILITY(U,$J,358.3,8732,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8732,1,3,0)
;;=3^Personal Hx of Malig Neop of Skin
;;^UTILITY(U,$J,358.3,8732,1,4,0)
;;=4^Z85.828
;;^UTILITY(U,$J,358.3,8732,2)
;;=^5063443
;;^UTILITY(U,$J,358.3,8733,0)
;;=Z85.71^^39^402^72
;;^UTILITY(U,$J,358.3,8733,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8733,1,3,0)
;;=3^Personal Hx of Hodgkin Lymphoma
;;^UTILITY(U,$J,358.3,8733,1,4,0)
;;=4^Z85.71
;;^UTILITY(U,$J,358.3,8733,2)
;;=^5063435
;;^UTILITY(U,$J,358.3,8734,0)
;;=Z65.8^^39^402^144
;;^UTILITY(U,$J,358.3,8734,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8734,1,3,0)
;;=3^Psychosocial Circumstance Related Problems
;;^UTILITY(U,$J,358.3,8734,1,4,0)
;;=4^Z65.8
;;^UTILITY(U,$J,358.3,8734,2)
;;=^5063185
;;^UTILITY(U,$J,358.3,8735,0)
;;=Z86.11^^39^402^109
;;^UTILITY(U,$J,358.3,8735,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8735,1,3,0)
;;=3^Personal Hx of Tuberculosis
;;^UTILITY(U,$J,358.3,8735,1,4,0)
;;=4^Z86.11
;;^UTILITY(U,$J,358.3,8735,2)
;;=^5063461
;;^UTILITY(U,$J,358.3,8736,0)
;;=Z86.13^^39^402^76
;;^UTILITY(U,$J,358.3,8736,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8736,1,3,0)
;;=3^Personal Hx of Malaria
;;^UTILITY(U,$J,358.3,8736,1,4,0)
;;=4^Z86.13
;;^UTILITY(U,$J,358.3,8736,2)
;;=^5063463
;;^UTILITY(U,$J,358.3,8737,0)
;;=Z86.73^^39^402^106
;;^UTILITY(U,$J,358.3,8737,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8737,1,3,0)
;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
;;^UTILITY(U,$J,358.3,8737,1,4,0)
;;=4^Z86.73
;;^UTILITY(U,$J,358.3,8737,2)
;;=^5063477
;;^UTILITY(U,$J,358.3,8738,0)
;;=Z86.79^^39^402^69
;;^UTILITY(U,$J,358.3,8738,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8738,1,3,0)
;;=3^Personal Hx of Circulatory System Diseases
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0JE 3760 printed Oct 16, 2024@17:50:41 Page 2
IBDEI0JE ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8726,1,3,0)
+2 ;;=3^Personal Hx of Malig Neop of Bladder
+3 ;;^UTILITY(U,$J,358.3,8726,1,4,0)
+4 ;;=4^Z85.51
+5 ;;^UTILITY(U,$J,358.3,8726,2)
+6 ;;=^5063428
+7 ;;^UTILITY(U,$J,358.3,8727,0)
+8 ;;=Z85.528^^39^402^83
+9 ;;^UTILITY(U,$J,358.3,8727,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,8727,1,3,0)
+12 ;;=3^Personal Hx of Malig Neop of Kidney
+13 ;;^UTILITY(U,$J,358.3,8727,1,4,0)
+14 ;;=4^Z85.528
+15 ;;^UTILITY(U,$J,358.3,8727,2)
+16 ;;=^5063430
+17 ;;^UTILITY(U,$J,358.3,8728,0)
+18 ;;=Z85.6^^39^402^74
+19 ;;^UTILITY(U,$J,358.3,8728,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,8728,1,3,0)
+22 ;;=3^Personal Hx of Leukemia
+23 ;;^UTILITY(U,$J,358.3,8728,1,4,0)
+24 ;;=4^Z85.6
+25 ;;^UTILITY(U,$J,358.3,8728,2)
+26 ;;=^5063434
+27 ;;^UTILITY(U,$J,358.3,8729,0)
+28 ;;=Z85.72^^39^402^98
+29 ;;^UTILITY(U,$J,358.3,8729,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,8729,1,3,0)
+32 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
+33 ;;^UTILITY(U,$J,358.3,8729,1,4,0)
+34 ;;=4^Z85.72
+35 ;;^UTILITY(U,$J,358.3,8729,2)
+36 ;;=^5063436
+37 ;;^UTILITY(U,$J,358.3,8730,0)
+38 ;;=Z85.79^^39^402^88
+39 ;;^UTILITY(U,$J,358.3,8730,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,8730,1,3,0)
+42 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
+43 ;;^UTILITY(U,$J,358.3,8730,1,4,0)
+44 ;;=4^Z85.79
+45 ;;^UTILITY(U,$J,358.3,8730,2)
+46 ;;=^5063437
+47 ;;^UTILITY(U,$J,358.3,8731,0)
+48 ;;=Z85.820^^39^402^77
+49 ;;^UTILITY(U,$J,358.3,8731,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,8731,1,3,0)
+52 ;;=3^Personal Hx of Malig Melanoma of Skin
+53 ;;^UTILITY(U,$J,358.3,8731,1,4,0)
+54 ;;=4^Z85.820
+55 ;;^UTILITY(U,$J,358.3,8731,2)
+56 ;;=^5063441
+57 ;;^UTILITY(U,$J,358.3,8732,0)
+58 ;;=Z85.828^^39^402^92
+59 ;;^UTILITY(U,$J,358.3,8732,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,8732,1,3,0)
+62 ;;=3^Personal Hx of Malig Neop of Skin
+63 ;;^UTILITY(U,$J,358.3,8732,1,4,0)
+64 ;;=4^Z85.828
+65 ;;^UTILITY(U,$J,358.3,8732,2)
+66 ;;=^5063443
+67 ;;^UTILITY(U,$J,358.3,8733,0)
+68 ;;=Z85.71^^39^402^72
+69 ;;^UTILITY(U,$J,358.3,8733,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,8733,1,3,0)
+72 ;;=3^Personal Hx of Hodgkin Lymphoma
+73 ;;^UTILITY(U,$J,358.3,8733,1,4,0)
+74 ;;=4^Z85.71
+75 ;;^UTILITY(U,$J,358.3,8733,2)
+76 ;;=^5063435
+77 ;;^UTILITY(U,$J,358.3,8734,0)
+78 ;;=Z65.8^^39^402^144
+79 ;;^UTILITY(U,$J,358.3,8734,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,8734,1,3,0)
+82 ;;=3^Psychosocial Circumstance Related Problems
+83 ;;^UTILITY(U,$J,358.3,8734,1,4,0)
+84 ;;=4^Z65.8
+85 ;;^UTILITY(U,$J,358.3,8734,2)
+86 ;;=^5063185
+87 ;;^UTILITY(U,$J,358.3,8735,0)
+88 ;;=Z86.11^^39^402^109
+89 ;;^UTILITY(U,$J,358.3,8735,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,8735,1,3,0)
+92 ;;=3^Personal Hx of Tuberculosis
+93 ;;^UTILITY(U,$J,358.3,8735,1,4,0)
+94 ;;=4^Z86.11
+95 ;;^UTILITY(U,$J,358.3,8735,2)
+96 ;;=^5063461
+97 ;;^UTILITY(U,$J,358.3,8736,0)
+98 ;;=Z86.13^^39^402^76
+99 ;;^UTILITY(U,$J,358.3,8736,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,8736,1,3,0)
+102 ;;=3^Personal Hx of Malaria
+103 ;;^UTILITY(U,$J,358.3,8736,1,4,0)
+104 ;;=4^Z86.13
+105 ;;^UTILITY(U,$J,358.3,8736,2)
+106 ;;=^5063463
+107 ;;^UTILITY(U,$J,358.3,8737,0)
+108 ;;=Z86.73^^39^402^106
+109 ;;^UTILITY(U,$J,358.3,8737,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,8737,1,3,0)
+112 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
+113 ;;^UTILITY(U,$J,358.3,8737,1,4,0)
+114 ;;=4^Z86.73
+115 ;;^UTILITY(U,$J,358.3,8737,2)
+116 ;;=^5063477
+117 ;;^UTILITY(U,$J,358.3,8738,0)
+118 ;;=Z86.79^^39^402^69
+119 ;;^UTILITY(U,$J,358.3,8738,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,8738,1,3,0)
+122 ;;=3^Personal Hx of Circulatory System Diseases
